Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMY--Mariska Hargitay Partners with BMS for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease.

Business Wire • a day ago

Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock

Last quarter, Millennium Management increased its position in Bristol Myers Squibb by over 5.8 million shares. This could be a sign that the multi-strategy hedge fund sees better times ahead for the pharmaceutical giant.

The Motley Fool • Jun 5, 2026

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $57.27, marking a +1.18% move from the previous day.

Zacks Investment Research • Jun 5, 2026

Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?

Pfizer has a higher forward dividend yield than Bristol Myers Squibb, but the latter beats the former in most other criteria. Bristol Myers Squibb has a stronger dividend growth track record, and based on its payout ratio, appears to have greater dividend durability potential as well.

The Motley Fool • Jun 4, 2026

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

Zacks Investment Research • Jun 4, 2026

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Jun 3, 2026

Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?

Both are working hard to get around patent cliffs. One of them seems to have made more progress on that front.

The Motley Fool • Jun 3, 2026

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company's investigational small-molecule HIF-2a inhibitor, to be eval.

Business Wire • Jun 3, 2026

BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos

Bristol Myers secured EU approval for Opdivo plus AVD in newly diagnosed advanced cHL and advanced Camzyos' label expansion review.

Zacks Investment Research • Jun 2, 2026

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival.

Business Wire • Jun 2, 2026